Evidence map›Paper›PMID 26754751›Full record

ArticleBMC genomics2016

Coupling high-throughput genetics with phylogenetic information reveals an epistatic interaction on the influenza A virus M segment.

Nicholas C Wu, Yushen Du, Shuai Le, Arthur P Young, Tian-Hao Zhang, Yuanyuan Wang, Jian Zhou, Janice M Yoshizawa, Ling Dong, Xinmin Li and 2 more

Abstract read
In one paragraph

Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2017
    Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicholas C WuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. wchnicholas@ucla.edu.
Yushen DuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. lily.duyushen@gmail.com.
Shuai LeDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. leshuai2004@qq.com.
Arthur P YoungDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. arthurpyoung@gmail.com.
Tian-Hao ZhangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. zth1992@gmail.com.
Yuanyuan WangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. wyynju@163.com.
Jian ZhouDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. JamieZhou@mednet.ucla.edu.
Janice M YoshizawaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. JYoshizawa@mednet.ucla.edu.
Ling DongDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. LingDong@mednet.ucla.edu.
Xinmin LiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. XinminLi@mednet.ucla.edu.
Ting-Ting WuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. TWu@mednet.ucla.edu.
Ren SunDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 90095, CA, USA. RSun@mednet.ucla.edu.

Funding

Fitness Profile of HIV-1 Genome with Host Cofactor Selection PressureR21AI110261 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SUN, REN · 2014 to 2015
$424k
NIAID NIH HHS R21 AI110261NIAID NIH HHS R21-AI-110261
6 · The paper itself

Abstract

backgroundEpistasis is one of the central themes in viral evolution due to its importance in drug resistance, immune escape, and interspecies transmission. However, there is a lack of experimental approach to systematically probe for epistatic residues.

resultsBy utilizing the information from natural occurring sequences and high-throughput genetics, this study established a novel strategy to identify epistatic residues. The rationale is that a substitution that is deleterious in one strain may be prevalent in nature due to the presence of a naturally occurring compensatory substitution. Here, high-throughput genetics was applied to influenza A virus M segment to systematically identify deleterious substitutions. Comparison with natural sequence variation showed that a deleterious substitution M1 Q214H was prevalent in circulating strains. A coevolution analysis was then performed and indicated that M1 residues 121, 207, 209, and 214 naturally coevolved as a group. Subsequently, we experimentally validated that M1 A209T was a compensatory substitution for M1 Q214H.

conclusionsThis work provided a proof-of-concept to identify epistatic residues by coupling high-throughput genetics with phylogenetic information. In particular, we were able to identify an epistatic interaction between M1 substitutions A209T and Q214H. This analytic strategy can potentially be adapted to study any protein of interest, provided that the information on natural sequence variants is available.

Indexed as

PhylogenyAmino Acid SubstitutionEpistasis, GeneticHigh-Throughput Screening AssaysHumansInfluenza A virusSequence DeletionViral Matrix ProteinsViral Matrix Proteins

Identifiers

PMID26754751
PMCPMC4710013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.